Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Respiratorius ABXSAT:RESP +6.14%32 EV-to-OCF is -5.20 as of Aug. 28, 2026. GuruFocus rates XSAT:RESP with a GF Score™ of 32/100. Among 1,408 Biotechnology companies, Respiratorius AB ranks better than 55.75% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Respiratorius AB's Enterprise Value is kr19.13 Mil.
Respiratorius AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was kr-3.68 Mil. Therefore, Respiratorius AB's EV-to-OCF for today is -5.20.
The historical rank and industry rank for Respiratorius AB's EV-to-OCF or its related term are showing as below:
XSAT:RESP'
s EV-to-OCF Range Over the Past 10 Years
Min: -9.36 Med: -4.9 Max: -1.03
Current: -4.9
During the past 13 years, the highest EV-to-OCF of Respiratorius AB was -1.03. The lowest was -9.36. And the median was -4.90.
XSAT:RESP's EV-to-OCF is ranked better than 55.75% of 1408
companies
in the Biotechnology industry
Industry Median: -3.715
vs XSAT:RESP: -4.90
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Respiratorius AB (XSAT:RESP) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Respiratorius AB's PE Ratio (TTM) for today is calculated as:
Respiratorius AB's share price for today is kr2.42.
Respiratorius AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.830.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Respiratorius AB EV-to-OCF Related Terms
Respiratorius AB EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Respiratorius AB's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:RESP vs VRTX, REGN, RVMD: EV-to-OCF Comparison
For the Biotechnology subindustry, Respiratorius AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Respiratorius AB EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Respiratorius AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Respiratorius AB's EV-to-OCF falls into.
Respiratorius AB's current Enterprise Value is kr19.13 Mil.
Respiratorius AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-3.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Respiratorius AB (XSAT:RESP) has a EV-to-OCF of -5.20 as of Aug. 28, 2026. According to the industry distribution chart, Respiratorius AB ranks #623 out of 1408 companies in the Biotechnology industry, placing it in the top 44.2%.
Is Respiratorius AB's EV-to-OCF too high?
Respiratorius AB's current EV-to-OCF is -5.20. Based on the distribution chart, Respiratorius AB ranks #623 out of 1408 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Respiratorius AB has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Respiratorius AB's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Respiratorius AB ranks #623 out of 1408 companies for EV-to-OCF. This puts Respiratorius AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Respiratorius AB's current EV-to-OCF is -5.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Respiratorius AB stock overvalued right now?
Respiratorius AB (XSAT:RESP) has a current EV-to-OCF of -5.20. The current EV-to-OCF is -5.20. Respiratorius AB's overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Respiratorius AB (XSAT:RESP), the current EV-to-OCF is -5.20 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Respiratorius AB develops pharmaceutical drugs to treat the common diseases namely Cancer, Chronic Obstructive Pulmonary Disease (COPD), and asthma as well as better methods for diagnosing cardiovascular diseases. The company's drug candidates includes RCD405, VAL001, RESP2000, RESP3000, RESP9000, and RESP1000.
32GF Score
Get the complete analysis for XSAT:RESP
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:RESP has been successfully added to your 
